Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet.

Inclusion Criteria * Healthy volunteers aged 18 to 55 years inclusive. * Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive). * Subjects who are healthy as determined by routine physical examination, including vital sign monitoring and laboratory analysis (i.e., hematology, blood biochemistry, and urinalysis). * Subjects should have negative urine test for drugs of abuse and alcohol breath analysis at screening and prior to each check-in. * All subjects should be free from any epidemic or contagious diseases (e.g., Malaria, Dengue, Covid-19) * Subjects agreed to sign the Informed Consent Form * Subjects agreed not to consume grapefruit and/or its products within 14 days prior to the start of study. * Subjects agreed to discontinue Vitamin, dietary supplements and herbal products 14 days prior to the first dose of study medication. Exclusion Criteria: * Inability to take oral medication * History of smoking (≤3 cigarette/day), alcoholism, and positive test for drug of abuse, heavy pan or gutka user as judged by teeth / mouth inspection. Subjects with clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological /connective tissue, musculoskeletal, metabolic/nutritional, endocrine, allergy, or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.. * Known hypersensitivity to any xenobiotic and Sacubitril/Valsartan or any of the excipients. * A prior history of angioedema due to an ACEI or ARB. * Subject received any of the investigational drug within four weeks. * Subjects with salt imbalance in the blood (especially high levels of potassium in the blood). * Donation or loss of more than 400 mL of blood within 3 months prior to the screening. * Ingestion of OTC drug, within 07 days of drug administration. * History of intake of any prescribed medicine during a period of 14 days, prior to drug administration * Subjects who test positive for syphilis (VDRL) or who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBs Ag) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2). * Subject with history of any illness that, in the opinion of investigator might confound the result of the study or post additional risk in administrating Sacubitril /Valsartan to the subjects.